Ocular Therapeutix (OCUL) TD Cowen 46th Annual Health Care Conference summary

Key data and study outcomes

• Achieved a positive outcome in a first-ever superiority study in retina, meeting a primary endpoint never previously reached, with a p-value of 0.0006.

• Data consistency across 129 slides demonstrated superiority of the drug in all analyses, including rescue-free and ITT populations.

• OCT results showed 56% of patients were stable up to 30 microns at 9 months with a single injection, indicating unprecedented disease control.

• In aggressive subpopulations, AXPAXLI showed better disease control than EYLEA, with all retinal hemorrhages at week 52 in the EYLEA arm.

• Nearly 80% of patients in SOL-1 were rescue-free, and the drug’s effect was tunable, lasting 36-40 weeks and trailing off by week 52.

Regulatory and commercial implications

• Expectation to secure the first and only superiority label in the field, providing protection from step therapy and supporting premium pricing.

• Superiority label would differentiate the drug from non-inferiority competitors and biosimilars, offering a long-term commercial advantage.

• Single trial approval pathway is being pursued with high conviction, meeting all criteria outlined in recent regulatory editorials.

• SPA (Special Protocol Assessment) and robust statistical results support the regulatory submission.

Physician and patient perspectives

• Physicians value the ability to choose initial therapy and avoid step therapy, with reimbursement benefits tied to a superiority label.

• Drug expected to perform better in real-world settings than in clinical trials, especially for patients frustrated with current anti-VEGF regimens.

• No workflow changes or new equipment required for adoption; drug offers potential for extended treatment intervals.